Results 91 to 100 of about 34,432 (188)

Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center

Journal of Pharmaceutical Care, 2023
Background: One of the FDA-approved treatments for COVID-19 is remdesivir. In this study, we investigated adverse drug events (ADEs) of remdesivir in COVID-19 patients who contacted 13-Aban pharmacy's drug and poison information center (DPIC).
Amirhosein Ghahremanian, Hasti Photography, Sona Ghasemi, Mohammadreza Heidari, Elliyeh ghadrdan   +4 more
doaj  

Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU [PDF]

, 2020
Zeno Pasquini, Roberto Montalti, Chiara Temperoni, Benedetta Canovari, Mauro Mancini, Michele Tempesta, D Pimpini, Nicoletta Zallocco, Francesco Barchiesi   +8 more
openalex   +1 more source

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Journal of Infection and Public Health, 2021
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009.
Mohd. Imran, Ahmed Subeh Alshrari, Syed Mohammed Basheeruddin Asdaq, Abida   +3 more
doaj  

A mechanism‐based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID‐19 treatment in humans [PDF]

, 2020
Patrick O. Hanafin, Brian Jermain, Anthony J. Hickey, Alexander V. Kabanov, Angela D. M. Kashuba, Timothy P. Sheahan, Gauri G. Rao   +6 more
openalex   +1 more source

A case report on the association between QTc prolongation and remdesivir therapy in a critically ill patient

IDCases, 2022
Remdesivir is a direct-acting inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase that is used to treat severe COVID-19 infections. We report a patient with severe COVID-19 pneumonia who experienced palpitations and syncope two days after starting ...
Shmeylan Al Harbi, Mashael AlFaifi, Hasan M. Al-Dorzi, Ohoud Aljuhani, Abeer A. Alenazi, Mai Alalawi, Khalid Al Sulaiman   +6 more
doaj  

Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses

, 2020
Eva Konkoľová, Milan Dejmek, Hubert Hřebabecký, Michal Šála, Jiří Böserle, Radim Nencka, Evžen Bouřa   +6 more
openalex   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID‐19: A scoping review [PDF]

, 2020
Juan Pimentel, Cassandra Laurie, Anne Cockcroft, Neil Andersson   +3 more
openalex   +1 more source

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

, 2020
Manli Wang, Ruiyuan Cao, Leike Zhang, Xing‐Lou Yang, Jia Liu, Mingyue Xu, Zheng‐Li Shi, Zhìhóng Hú, Wu Zhong, Gengfu Xiao   +9 more
openalex   +1 more source

Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes

, 2020
Seong Woo Choi, Jin Soo Shin, Soon‐Jung Park, Eunhye Jung, Yun-Gwi Park, Jiho Lee, Sung Joon Kim, Hun‐Jun Park, Jung‐Hoon Lee, Sung‐Min Park, Sung‐Hwan Moon, Kiwon Ban, Yun Young Go   +12 more
openalex   +1 more source